Is There a Role for Triple Therapy After ACS? Article

Full Text via DOI: 10.1007/s11886-022-01634-3 Web of Science: 000751969400002
International Collaboration

Cited authors

  • Bhogal S, Alkhouli M, White CJ, Bailey S, Mamas M, Haddad E, Paul TK


  • Purpose of Review The optimal antithrombotic strategy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains the subject of controversy. In this article, we review the current evidence for the use of triple therapy in acute coronary syndrome (ACS) patients. Recent Findings The recently published trials of AF patients undergoing PCI have shown that combination of non-vitamin K oral anticoagulants (NOACs) with an antiplatelet agent is either superior or non-inferior to vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) in reducing bleeding complications with no difference in regard to thromboembolic events. Currently, the use of dual therapy (preferably with a NOAC and clopidogrel) is recommended over triple therapy in these patients. The optimal duration should be guided by the assessment of an individual's risk of thrombosis and bleeding events.

Publication date

  • 2022

Published in

International Standard Serial Number (ISSN)

  • 1523-3782

Number of pages

  • 10